Research ArticleAccepted Article
A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen
The Journal of Rheumatology February 2021, jrheum.201088; DOI: https://doi.org/10.3899/jrheum.201088
Peter C. Taylor
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Désirée van der Heijde
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Robert Landewé
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Shannon McCue
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Sue Cheng
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Annelies Boonen
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; Amsterdam University Medical Centre & Zuyderland Medical Centre, Heerlen, The Netherlands; Celgene Corporation, Summit, New Jersey, USA; Amgen Inc., Thousand Oaks, California, USA; Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. This study was funded by Celgene. Amgen Inc. acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. P.C. Taylor has received grant/research support from Celgene. D. van der Heijde has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma, and is a director of Imaging Rheumatology BV. R. Landewé has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer and UCB Pharma and received an honorarium from Celgene for reading films for this study. S. McCue is a former employee of Celgene. S. Cheng is an employee of Amgen Inc. and a former employee of Celgene. A. Boonen has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK; Tel.: 01865 227323; E-mail: peter.taylor@kennedy.ox.ac.uk
Article Figures & Data
Additional Files
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Feb 2021, jrheum.201088; DOI: 10.3899/jrheum.201088
Accepted manuscript
A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Feb 2021, jrheum.201088; DOI: 10.3899/jrheum.201088